{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sogawa C"],"funding":["Suzuken Memorial Foundation","Ryobi Teien Memory Foundation","Japan Society for the Promotion of Science"],"pagination":["E523"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7072357"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(2)"],"pubmed_abstract":["Tumor growth, progression, and therapy resistance are crucial factors in the prognosis of cancer. The properties of three-dimensional (3D) tumor-like organoids (tumoroids) more closely resemble in vivo tumors compared to two-dimensionally cultured cells and are therefore effectively used for assays and drug screening. We here established a repurposed drug for novel anticancer research and therapeutics using a 3D tumoroid-based screening system. We screened six pharmacologically active compounds by using an original tumoroid-based multiplex phenotypic screening system with a matrix metalloproteinase 9 (MMP9) promoter-driven fluorescence reporter for the evaluation of both tumoroid formation and progression. The antiparkinson drug benztropine was the most effective compound uncovered by the "],"journal":["Cancers"],"pubmed_title":["Antiparkinson Drug Benztropine Suppresses Tumor Growth, Circulating Tumor Cells, and Metastasis by Acting on SLC6A3/DAT and Reducing STAT3."],"pmcid":["PMC7072357"],"funding_grant_id":["CS","TE","KO","17K11643","JP17K11642","JP17K11669","JP17K17895","JP17K11689","19H03817","19H04051","JP18K09789"],"pubmed_authors":["Trin K","Tran MT","Taha EA","Ishige M","Sogawa C","Kawai H","Lu Y","Okamoto K","Sogawa N","Calderwood SK","Okusha Y","Kozaki KI","Eguchi T","Takigawa M"],"additional_accession":[]},"is_claimable":false,"name":"Antiparkinson Drug Benztropine Suppresses Tumor Growth, Circulating Tumor Cells, and Metastasis by Acting on SLC6A3/DAT and Reducing STAT3.","description":"Tumor growth, progression, and therapy resistance are crucial factors in the prognosis of cancer. The properties of three-dimensional (3D) tumor-like organoids (tumoroids) more closely resemble in vivo tumors compared to two-dimensionally cultured cells and are therefore effectively used for assays and drug screening. We here established a repurposed drug for novel anticancer research and therapeutics using a 3D tumoroid-based screening system. We screened six pharmacologically active compounds by using an original tumoroid-based multiplex phenotypic screening system with a matrix metalloproteinase 9 (MMP9) promoter-driven fluorescence reporter for the evaluation of both tumoroid formation and progression. The antiparkinson drug benztropine was the most effective compound uncovered by the ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Feb","modification":"2025-04-26T01:06:20.327Z","creation":"2020-05-22T13:28:38Z"},"accession":"S-EPMC7072357","cross_references":{"pubmed":["32102440"],"doi":["10.3390/cancers12020523"]}}